Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Projected Valuation Of The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market In The Coming Years?

The market for treatment of hereditary breast and ovarian cancer syndrome has seen robust growth in the past few years. The market, worth $6.72 billion in 2024, is projected to expand to $7.07 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.2%. The historic growth trajectory is credited to factors such as heightened awareness and screenings, government initiatives that support this cause, patient advocacy and empowerment initiatives, as well as collaborative research efforts.

The market for treatment of hereditary breast and ovarian cancer syndrome is predicted to experience significant expansion in the coming years, ballooning to a value of $8.98 billion by 2029, representing a compound annual growth rate (CAGR) of 6.2%. The anticipated growth during this period is largely due to factors such as the increased application of artificial intelligence, wider availability of genetic counseling, approval of targeted therapies by regulatory bodies, the implementation of personalized treatment strategies, and international research collaborations. Future trends expected to influence this forecast period include gene modification technologies, developments in immunotherapy, advances in oncology technology, immunotherapy’s application to BRCA-related cancers, and extensive cross-disciplinary care.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13209&type=smp

Which Growth Drivers Are Shaping The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Outlook?

An increase in genetic disorders is anticipated to fuel the expansion of the hereditary breast and ovarian cancer syndrome treatment market in the future. Newborn screening, a health exam carried out shortly after birth to check for certain health conditions, is utilised by healthcare professionals to pinpoint and manage specific needs before they impact the baby’s health. This screening has the potential to indicate infants at elevated risk of developing breast and ovarian cancer, thereby enabling early initiation of preventative measures. To illustrate, the Texas Department of State Health Services, a health agency based in the US, reported that the total specimens received for newborn screening in 2022 rose by 4.3% to 761,000, up from 729,347 in 2021. Moreover, approximately 394,000 infants were screened, with 1,130 of them diagnosed with one of the NBS disorders in 2022. As a result, the surge in genetic disorders is bolstering the growth of the hereditary breast and ovarian cancer syndrome treatment market.

What Is The Segment Breakdown Of The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?

The hereditary breast and ovarian cancer syndrome treatmentmarket covered in this report is segmented –

1) By Treatment: Hormonal Therapy; Chemoprevention; Genetic Counselling; Medication; Other Treatments

2) By Diagnosis: Genetic Testing; Magnetic Resonance Imaging (MRI); Mammography; Other Diagnosis

3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration

4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors

2) By Chemoprevention: Tamoxifen; Raloxifene

3) By Genetic Counselling: Risk Assessment; Family Planning Guidance

4) By Medication: Targeted Therapies; Immune Checkpoint Inhibitors

5) By Other Treatments: Preventive Surgery; Surveillance Strategies

How Are Global Trends Impacting The Development Of The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?

Key players in the hereditary breast and ovarian cancer syndrome treatment market are embracing novel treatment options, such as comprehensive risk tests, to deliver dependable services to their clients. A thorough risk assessment test is a method that helps determine an individual’s likelihood of developing a condition or showing a disease symptom. For example, in February 2023, Genetic Technologies Limited, a firm specializing in molecular diagnostics based in Australia, introduced an innovative comprehensive risk assessment test, a form of treatment for breast and ovarian cancer. This incorporates gene mutation testing for the two types of cancer, along with hereditary and non-hereditary risk factors, and the GeneType risk score for both. The test adopts a unique approach that melds the identification of the 13 main actionable genes responsible for breast and ovarian cancer susceptibility with the GeneType test platform. This cutting-edge test platform caters to women over the age of 30 who, aside from rare genetic changes, are at a greater risk of developing breast and ovarian cancer compared to the broader population.

Who Are The Major Stakeholders Operating In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?

Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market report are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Vertex Pharmaceuticals Inc., Mercy Health, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Seagen Inc., LEO Pharma Inc., LifeLabs Genetics, Natera Inc., Fresenius Kabi AG, Myriad Genetics Inc., Invitae Corporation, Editas Medicine Inc., GenMark Diagnostics Inc., Genentech Inc., CRISPR Therapeutics AG, Advocate Health Care

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/hereditary-breast-and-ovarian-cancer-syndrome-treatment-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?

North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary breast and ovarian cancer syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13209&type=smp

Browse Through More Reports Similar to the Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market 2025, By The Business Research Company

Anorectal Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anorectal-disorders-treatment-global-market-report

Aspergillosis Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/aspergillosis-treatment-global-market-report

Histoplasmosis Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/histoplasmosis-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model